GlassScriptPhysician profile
Kayla Clair Spalding
NPI 1891392916
$3,036.26
in general payments reported to CMS, 2019-2025
22 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $513 · 2023: $151 · 2024: $2,079 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Travel and Lodging: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.24 |
| Travel and Lodging | $1,055.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,618.55 | 2024 | Axonics |
| Abbvie INC. | $175.70 | 2021-2022 | |
| Inari Medical, INC. | $170.80 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Aspira Women'S Health INC | $169.44 | 2022-2024 | Ova1 |
| Agile Therapeutics, INC. | $117.33 | 2021-2024 | Twirla |
| Biogen, INC. | $107.96 | 2024 | Zurzuvae |
| Exeltis, USA INC. | $106.10 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $101.56 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.71 | 2021-2024 | |
| Hologic Sales and Service, LLC | $58.80 | 2022-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima |
| Sage Therapeutics, LLC | $56.93 | 2023-2024 | |
| Pfizer INC. | $39.23 | 2022-2023 | |
| Myovant Sciences INC. | $37.63 | 2022 | |
| Organon LLC | $29.80 | 2021-2025 | Nexplanon |
| Gynesonics, INC. | $25.36 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.97 | 2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $18.70 | 2023 | Myfembree |
| Millicent US INC | $18.36 | 2025 | Femlyv |
| Evofem Biosciences, INC. | $17.50 | 2022 | |
| Stryker Corporation | $16.86 | 2025 | Clottriever Bold Catheter |
| Daiichi Sankyo INC. | $16.06 | 2022 | |
| Mylan Pharmaceuticals INC. | $15.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Spalding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.